Company Overview - GENFIT is a late-stage biopharmaceutical company focused on improving the lives of patients with rare and life-threatening liver diseases [3] - The company has a rich history in liver disease research and development, spanning over two decades [3] - GENFIT's R&D portfolio includes programs at various stages of development, particularly focusing on Acute-on-Chronic Liver Failure (ACLF) [3] Recent Shareholder Meeting - The Combined Shareholders Meeting took place on May 22, 2024, with a quorum of 27.25% [1] - All resolutions presented at the meeting were approved by the shareholders [1] Product Development - GENFIT's ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE, utilizing different mechanisms of action [3] - The company also targets other serious diseases such as cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA) [3] - The success of the 52-week Phase 3 ELATIVE® study evaluating elafibranor in Primary Biliary Cholangitis (PBC) demonstrates GENFIT's expertise in developing high-potential molecules [3] Diagnostic Franchise - GENFIT has a diagnostic franchise that includes NIS2+® for Metabolic dysfunction-associated steatohepatitis (MASH) and TS-01 focusing on blood ammonia levels [3] Corporate Structure - GENFIT is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA [3] - The company is listed on the Nasdaq Global Select Market and Euronext regulated market in Paris [3] - In 2021, Ipsen acquired an 8% stake in GENFIT, becoming one of its largest shareholders [3]
GENFIT: May 22, 2024 Combined Shareholders Meeting Results